93 related articles for article (PubMed ID: 10338049)
1. Comparison of two doses of intravenous immunoglobulin after allogeneic bone marrow transplants.
Abdel-Mageed A; Graham-Pole J; Del Rosario ML; Longmate J; Ochoa S; Amylon M; Elfenbein GJ; Janiec J; Jansen J; Lazarus HM
Bone Marrow Transplant; 1999 May; 23(9):929-32. PubMed ID: 10338049
[TBL] [Abstract][Full Text] [Related]
2. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
[TBL] [Abstract][Full Text] [Related]
3. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections.
Anderson D; DeFor T; Burns L; McGlave P; Miller J; Wagner J; Weisdorf D
Biol Blood Marrow Transplant; 2003 Jan; 9(1):52-9. PubMed ID: 12533742
[TBL] [Abstract][Full Text] [Related]
4. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
[TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients.
Winston DJ; Ho WG; Bartoni K; Champlin RE
Bone Marrow Transplant; 1993 Sep; 12(3):283-8. PubMed ID: 8241988
[TBL] [Abstract][Full Text] [Related]
6. Some but not all benefits of intravenous immunoglobulin therapy after marrow transplantation appear to correlate with IgG trough levels.
Cottler-Fox M; Lynch M; Pickle LW; Cahill R; Spitzer TR; Deeg HJ
Bone Marrow Transplant; 1991 Jul; 8(1):27-33. PubMed ID: 1655138
[TBL] [Abstract][Full Text] [Related]
7. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources.
Rocha V; Wagner JE; Sobocinski KA; Klein JP; Zhang MJ; Horowitz MM; Gluckman E
N Engl J Med; 2000 Jun; 342(25):1846-54. PubMed ID: 10861319
[TBL] [Abstract][Full Text] [Related]
8. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
Atkinson K; Downs K
Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
[TBL] [Abstract][Full Text] [Related]
9. Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease.
Kumar S; Wolf RC; Chen MG; Gastineau DA; Gertz MA; Inwards DJ; Lacy MQ; Tefferi A; Litzow MR
Bone Marrow Transplant; 2002 Aug; 30(3):161-5. PubMed ID: 12189534
[TBL] [Abstract][Full Text] [Related]
10. The role of immunoglobulin in bone marrow transplantation.
Saral R
Transplant Proc; 1991 Aug; 23(4):2128-32. PubMed ID: 1871829
[TBL] [Abstract][Full Text] [Related]
11. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.
Bensinger WI; Martin PJ; Storer B; Clift R; Forman SJ; Negrin R; Kashyap A; Flowers ME; Lilleby K; Chauncey TR; Storb R; Appelbaum FR
N Engl J Med; 2001 Jan; 344(3):175-81. PubMed ID: 11172139
[TBL] [Abstract][Full Text] [Related]
12. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver?
Klaesson S; Ringdén O; Ljungman P; Aschan J; Hägglund H; Winiarski J
Transplantation; 1995 Dec; 60(11):1225-30. PubMed ID: 8525515
[TBL] [Abstract][Full Text] [Related]
13. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
14. [Intravenous immunoglobulins in bone marrow transplantation].
Andolina M; Giorgi R; Maximova N; Comar M
Pediatr Med Chir; 1993; 15(4):347-8. PubMed ID: 8265452
[TBL] [Abstract][Full Text] [Related]
15. Continuous infusion intravenous immunoglobulin is associated with a reduced incidence of infection and achieves higher serum immunoglobulin G levels than intermittent infusion following bone marrow transplantation.
Spitzer TR; Cottler-Fox M; Sullivan P; Lynch M; Tefft MC; Pickle LW; Cirenza E; Cahill R; Deeg HJ; Sacher R
Semin Hematol; 1992 Jul; 29(3 Suppl 2):123-6. PubMed ID: 1509292
[No Abstract] [Full Text] [Related]
16. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
Byrne JL; Stainer C; Hyde H; Miflin G; Haynes AP; Bessell EM; Russell NH
Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT).
Zikos P; Van Lint MT; Lamparelli T; Gualandi F; Occhini D; Mordini N; Berisso G; Bregante S; Bacigalupo A
Haematologica; 1998 Feb; 83(2):132-7. PubMed ID: 9549924
[TBL] [Abstract][Full Text] [Related]
18. A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study Group.
List AF; Maziarz R; Stiff P; Jansen J; Liesveld J; Andrews F; Schuster M; Wolff S; Litzow M; Karanes C; Dahlberg S; Kirkhart B; Bianco JA; Singer JW
Bone Marrow Transplant; 2000 Feb; 25(3):283-91. PubMed ID: 10673700
[TBL] [Abstract][Full Text] [Related]
19. Graft-versus-host disease after marrow transplantation.
Storb R
Prog Clin Biol Res; 1986; 224():139-57. PubMed ID: 3540990
[TBL] [Abstract][Full Text] [Related]
20. Time of onset, viral load, relapse, and duration of active cytomegalovirus infection in bone marrow transplant outcomes.
Habib K; Lamia T; Amel L; Abdelrahmen A; Saloua L; Hana E; Amine S; Bechir Z; Tarek BO; Assia BH
Exp Clin Transplant; 2008 Mar; 6(1):67-73. PubMed ID: 18405248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
